Mulighed for aendring af ordinationsmønster

Lene Ørskov Reuther; Hanne Rolighed Christensen; Camilla Mikkelsen

Mulighed for aendring af ordinationsmønster

Lene Ørskov Reuther, Hanne Rolighed Christensen, Camilla Mikkelsen

Institut for Klinisk Medicin

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner.
Udgivelsesdato: 2009-Sep

Bidragets oversatte titel	Changing clinicians' prescription patterns
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	171
Udgave nummer	37
Sider (fra-til)	2655-6
Antal sider	2
ISSN	0041-5782
Status	Udgivet - 2009

Bibliografisk note

Keywords: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Denmark; Drug Costs; Humans; Immunoglobulin G; Physician's Practice Patterns; Practice Guidelines as Topic; Receptors, Tumor Necrosis Factor; Therapeutic Equivalency

Citationsformater

@article{73a8a28088d411df928f000ea68e967b,

title = "Mulighed for aendring af ordinationsm{\o}nster",

abstract = "In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner. Udgivelsesdato: 2009-Sep",

author = "Reuther, {Lene {\O}rskov} and Christensen, {Hanne Rolighed} and Camilla Mikkelsen",

note = "Keywords: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Denmark; Drug Costs; Humans; Immunoglobulin G; Physician's Practice Patterns; Practice Guidelines as Topic; Receptors, Tumor Necrosis Factor; Therapeutic Equivalency",

year = "2009",

language = "Dansk",

volume = "171",

pages = "2655--6",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "37",

}

TY - JOUR

T1 - Mulighed for aendring af ordinationsmønster

AU - Reuther, Lene Ørskov

AU - Christensen, Hanne Rolighed

AU - Mikkelsen, Camilla

N1 - Keywords: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Denmark; Drug Costs; Humans; Immunoglobulin G; Physician's Practice Patterns; Practice Guidelines as Topic; Receptors, Tumor Necrosis Factor; Therapeutic Equivalency

PY - 2009

Y1 - 2009

N2 - In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner. Udgivelsesdato: 2009-Sep

AB - In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner. Udgivelsesdato: 2009-Sep

M3 - Tidsskriftartikel

C2 - 19758512

VL - 171

SP - 2655

EP - 2656

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 37

ER -